Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

9.750 +0.370 (+3.94%)
Streaming Delayed Price Updated: 3:08 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 890,980
Open 9.200
Bid (Size) 9.750 (1)
Ask (Size) 9.780 (2)
Prev. Close 9.380
Today's Range 9.145 - 9.810
52wk Range 2.080 - 9.720
Shares Outstanding 67,176,067
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a... 
Via Stocktwits
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026. 
Via Benzinga

Performance

YTD
+149.4%
+149.4%
1 Month
+22.5%
+22.5%
3 Month
+91.2%
+91.2%
6 Month
+225.0%
+225.0%
1 Year
+351.4%
+351.4%

More News

Read More
Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder
Via Stocktwits
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 7, 2025
Via Benzinga
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Via The Motley Fool
Topics Intellectual Property
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted
Via Chartmill
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Via Benzinga
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial
Via Stocktwits
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Shares in Amylyx Pharmaceuticals Soared This Week
Via The Motley Fool
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Via Benzinga
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
Via Benzinga
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Via Benzinga
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 9.750
When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 09/02/25 03:08 PM ET
What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 654.97M
How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?
Amylyx Pharmaceuticals, Inc. - Common Stock has 655M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.